Blockchain Registration Transaction Record

Leksum Inks Vienna Deal to Advance LK-ICU Trials

Leksum signs agreement with Medical University of Vienna for Phase I/II trials of LK-ICU, a therapy preserving diaphragm muscle during mechanical ventilation.

This news matters because ICU-acquired weakness and prolonged mechanical ventilation can lead to devastating muscle loss, extended hospital stays, and reduced quality of life for hundreds of thousands of patients each year. LK-ICU's potential to preserve diaphragm muscle function could revolutionize critical care by shortening weaning times and improving recovery. Moreover, Leksum's broader pipeline targeting sarcopenia, cancer cachexia, and muscle loss from GLP-1 drugs addresses a wide range of muscle-wasting conditions that currently lack effective therapies. The agreement with the Medical University of Vienna not only accelerates LK-ICU's clinical development but also strengthens the transatlantic collaboration necessary to bring innovative biologics to patients faster. As the population ages and the use of weight-loss drugs rises, therapies that protect muscle mass will become increasingly vital, making Leksum's work highly relevant to public health and the future of regenerative medicine.